- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07393126
Účinky konzumace testovacího přípravku na močení u zdravých japonských dospělých
Efekty konzumace testovaného produktu na močení u zdravých japonských dospělých: Randomizovaná, placebem kontrolovaná, dvojitě zaslepená, paralelně skupinová komparační studie
The goal of this clinical trial is to test in Japanese adults who experience concerns regarding urinary frequency. The main question it aims to answer is:
•Does consumption of Cranberry Phospholipids reduce daytime urinary frequency?
Participants will be given the following tasks:
- Take two tablets daily containing Cranberry Phospholipid for eight weeks.
- Answer the questionnaire on the overactive bladder (OAB)-specific quality of life (QOL).
- Answer the questionnaire on OAB symptoms.
- Answer the questionnaire on urinary frequency during the study period. Researchers will compare Cranberry Phospholipids and placebo groups to see if Cranberry Phospholipids reduces daytime urinary frequency.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Naoko Suzuki
- Telefonní číslo: +81-3-3818-0610
- E-mail: group_gakujutsu@orthomedico.jp
Studijní záloha kontaktů
- Jméno: Asami Baba, PhD
- Telefonní číslo: +81-3-3818-0610
- E-mail: asami-baba@orthomedico.jp
Studijní místa
-
-
Tokyo
-
Nerima-ku, Tokyo, Japonsko, 176-0002
- Nábor
- Nerima Medical Association Minami-machi Clinic
-
Kontakt:
- Naoko Suzuki
- Telefonní číslo: +81-3-3818-0610
- E-mail: group_gakujutsu@orthomedico.jp
-
Kontakt:
- Asami Baba, PhD
- Telefonní číslo: +81-3-3818-0610
- E-mail: asami-baba@orthomedico.jp
-
Vrchní vyšetřovatel:
- Masafumi Nagata, MD
-
Shinagawa-Ku, Tokyo, Japonsko, 141-0022
- Nábor
- Medical Corporation Seishinkai, Takara Clinic
-
Kontakt:
- Naoko Suzuki
- Telefonní číslo: +81-3-3818-0610
- E-mail: group_gakujutsu@orthomedico.jp
-
Kontakt:
- Asami Baba, PhD
- Telefonní číslo: +81-3-3818-0610
- E-mail: asami-baba@orthomedico.jp
-
Vrchní vyšetřovatel:
- Tsuyoshi Takara, MD
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Japanese
- Men or women
- Adults
- Healthy individuals
- Individuals with positive urine leukocytes at baseline
- Individuals whose score of urinary urgency of overactive bladder symptom score (OABSS) is less than two or total score of OABSS is less than three at baseline
- Individuals whose "frequent urination during the daytime hours" of "symptom bother" of OAB-q is relatively high at baseline
Exclusion Criteria:
- Individuals undergoing medical treatment or having a medical history of malignant tumor, heart failure, or myocardial infarction
- Individuals carrying a pacemaker or an implantable cardioverter defibrillator
- Individuals undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
- Individuals who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage as part of their daily diet
- Individuals currently regularly taking medications (including herbal medicines) and supplements
- Individuals who are allergic to medicines and/or the test-product-related products in this trial
- Individuals with urinary pain
- Individuals undergoing treatment, have had treatment within two months, or need the treatment for diseases related to urination, e.g. benign prostatic hypertrophy, prostatitis, prostate cancer, overactive bladder, hypoactive bladder, cystitis, interstitial cystitis, bladder cancer, bladder stones, urethritis, urethral stricture, neurological disease, polyuria, and nocturnal polyuria
- Individuals have overactive bladder symptom (individuals who urinate eight times or more per day, and have urinary urgency at least once a week)
- Individuals wake up twice or more to urinate at bedtime
- Individuals are pregnant, breast-feeding, and planning to become pregnant
- Individuals have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial
- Individuals are judged as ineligible to participate in the trial by the physician
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Jiný
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Cranberry Phospholipids
Take two tablets (containing 120 mg cranberry phospholipids/tablet) |
Take two tablets will be taken once daily |
|
Komparátor placeba: Placebo
Take two tablets (containing 0 mg cranberry phospholipids/tablet) |
Take two tablets will be taken once daily |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Measured value for the Overactive Bladder Questionnaire (OAB-q) questionnaire item "frequent urination during the daytime hours" after the 8-week intervention
Časové okno: After the 8-week intervention
|
Using OAB-q, we evaluate OAB-specific quality of life (QOL). The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL. |
After the 8-week intervention
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Individuals whose the response to the OAB-q questionnaire item "frequent urination during the daytime hours" improved by one or more scale points after the 8-week intervention compared to Baseline
Časové okno: Baseline, and after the 8-week intervention
|
Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL. |
Baseline, and after the 8-week intervention
|
|
The amount of change, and percentage of change from Baseline for the OAB-q questionnaire item "frequent urination during the daytime hours" after the 8-week intervention
Časové okno: Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
|
Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL. |
Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
|
|
The measured values, amount of changes, and percentage of changes from Baseline for all other questionnaire items of the OAB-q, excluding "frequent urination during the daytime hours," after the 8-week intervention
Časové okno: Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
|
Using OAB-q, we evaluate OAB-specific QOL. The questionnaire have 33 items, including 8 items measuring "symptom bother" and 25 items measuring "impact on QOL," with each item rated on a 6-point scale."Impact on QOL" is scored across four domains: "Coping" (8 items), "Concern" (7 items), "Sleep" (5 items), and "Social Interaction" (5 items). Scores are calculated on a scale of 0 to 100, with higher scores indicating a greater degree of difficulty. On the other hand, the "impact on QOL" indicates that the higher the score, the better the QOL. |
Baseline, after the 1-week intervention, the 3-week intervention and the 8-week intervention
|
|
The measured values, and amount of changes and percentage of changes from Period 1 for the average frequency of urination during the daytime, during the nighttime, and all day, as measured during Periods 2 to 9
Časové okno: Period 1 (7 days prior to Baseline), Period 2~9 (periods separated by 7 days from the start of intervention)
|
Participants will maintain a daily diary of their urination frequency during two distinct periods: for 7 days immediately preceding the Baseline, and from the beginning of the intervention until the day before the final examination. |
Period 1 (7 days prior to Baseline), Period 2~9 (periods separated by 7 days from the start of intervention)
|
|
Individuals who experienced adverse events
Časové okno: After the 8-week intervention
|
During the trial period, if a participant exhibits any clinically significant "new manifestation of abnormality" or "aggravation" in his/her physical signs and symptoms, it is considered to be an adverse event. |
After the 8-week intervention
|
|
Individuals whose values of urinalysis and peripheral blood test are outside the reference range after intervention despite within the reference range at Baseline
Časové okno: Baseline, and after the 8-week intervention
|
The ratio of cases which had test items stated in urinalysis and peripheral blood examination within their respective standard ranges before intervention but exceeded the ranges after intervention are calculated, intergroup comparison at each time point is performed using tests for comparing proportions. |
Baseline, and after the 8-week intervention
|
|
Body height
Časové okno: Baseline, and after the 8-week intervention
|
Body height is measured using a height meter. |
Baseline, and after the 8-week intervention
|
|
Body weight
Časové okno: Baseline, and after the 8-week intervention
|
Body weight is measured using a body scale. |
Baseline, and after the 8-week intervention
|
|
Blood pressure
Časové okno: Baseline, and after the 8-week intervention
|
Systolic and diastolic blood pressure are measured using a digital wrist-type sphygmomanometer. |
Baseline, and after the 8-week intervention
|
|
Urinalysis
Časové okno: Baseline, and after the 8-week intervention
|
A urine sample (approximately 10 mL) will be collected from each participant, and the samples will be sent to LSI Medience Corporation for analysis. |
Baseline, and after the 8-week intervention
|
|
Peripheral blood examination
Časové okno: Baseline, and after the 8-week intervention
|
A venous blood sample (approximately 10 mL) will be collected from each participant, and the samples will be sent to LSI Medience Corporation for analysis. |
Baseline, and after the 8-week intervention
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Studijní židle: Tsuyoshi Takara, MD, Medical Corporation Seishinkai, Takara Clinic
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další identifikační čísla studie
- 01170-0018-29
- UMIN000060011 (Identifikátor registru: UMIN-CTR)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Data sharing will be discussed among the research affiliates after the study is completed.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .